DeutschNewstral
Article
Bbarrons.com on 2020-04-22 15:28
Biogen Earnings Were Good, but an Alzheimer’s Drug Delay Hits Shares
Related news
- BAfter Lengthy Delay, Biogen Submits Troubled Alzheimer’s Drug for FDA Approvalbarrons.com
- BBiogen Stock Is Soaring as Hope Returns for Alzheimer’s Drugbarrons.com
- BBiogen Stock Is Falling Because Earnings Guidance Came Up Shortbarrons.com
Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drugSeattle Times
Biogen cuts the price for its Alzheimer’s drug in halfpressherald.com- BBiogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong.2 min readbarrons.com
- BBiogen Is Spiking Because Its Alzheimer’s Drug Takes Another Step Toward Approvalbarrons.com
- FBiogen shares leap after ‘substantial evidence’ Alzheimer’s drug is effectiveft.com
- Biogen cuts the price tag on its Alzheimer’s drug in halfSeattle Times
- BBiogen Reports Earnings This Week. Here’s What To Expect.barrons.com
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandalArs Technica
Biogen applies to market Alzheimer’s disease treatment in the USNew York Post- BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min readbarrons.com
Biogen Alzheimer’s drug puts FDA’s judgment in harsh spotlightMerced Sun-Star- BBiogen Stock Gets a Lift From Strong Earnings Reportbarrons.com
Biogen to replace CEO after Alzheimer’s drug flopsjournalrecord.com
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approvalobserver.com- Biogen cuts Alzheimer’s drug price 50% months after approvalSeattle Times
Biogen shares plunge after company makes change to Alzheimer’s drug trialsbizjournals.com